Crestchem reported an 18% rise in FY26 revenue to ₹29.61 crore, while net profit remained stable at ₹2.71 crore. The company proposed a final dividend of ₹1.50 per share and formed a new subsidiary, Oleo Biosciences.
Crestchem Ltd Posts 18% Revenue Growth in FY26, Stable Profit
Crestchem Ltd's annual revenue for FY26 reached ₹29.61 crore, an 18.06% increase from ₹25.08 crore in FY25. The company's net profit for the fiscal year ended March 31, 2026, was ₹2.71 crore, a slight decrease of 0.73% from ₹2.73 crore in the previous year. Basic Earnings Per Share (EPS) stood at ₹9.03.
Reader Takeaway: Strong revenue growth driven by operations; stable profit maintained, but flatlining net income is a watch point.
What just happened
Crestchem Limited announced its financial results for the fiscal year 2026. The company reported consolidated revenue from operations of ₹29.61 crore, up from ₹25.08 crore in the prior fiscal year. Net profit for FY26 was ₹2.71 crore, nearly flat compared to ₹2.73 crore in FY25.
The company also proposed a final dividend of ₹1.50 per equity share (15%). Additionally, Crestchem has incorporated a wholly-owned subsidiary, 'Oleo Biosciences Private Limited', in Bangalore, Karnataka, on March 31, 2026, holding a 75% stake.
An investment of up to ₹2.25 crore has been approved for this subsidiary, to be made through loans or equity. The reappointment and remuneration of key management personnel for a five-year term were also approved.
Why this matters
The revenue growth indicates expanding business operations. A stable profit, despite revenue increase, suggests efficient cost management or margin pressures. The proposed dividend offers direct returns to shareholders. The formation of a new subsidiary signals strategic expansion into new areas, although its operational status needs monitoring.
The backstory
Crestchem Limited operates in the chemical sector. Its financial performance historically shows a steady, albeit modest, growth trajectory. The company's focus on enhancing operational scale has been a key driver of its revenue figures.
What changes now
Shareholders can expect a dividend payout, subject to AGM approval. The new subsidiary, Oleo Biosciences, represents a new avenue for growth, with management planning significant investment. The market will likely watch the performance and commercialization of this new entity closely.
Risks to watch
The primary watch point is the new subsidiary, Oleo Biosciences Private Limited, which has not yet commenced commercial operations. Its success and timeline for revenue generation are critical. A flat net profit despite revenue growth may indicate rising costs or competitive pressures.
Peer comparison
While specific peer data is not provided in the filing, companies in the specialty chemical sector often face margin pressures due to raw material costs and competition. Growth in revenue coupled with stable profit is a common scenario for established players focusing on operational efficiency.
Context metrics (time-bound)
- FY26 Revenue: ₹29.61 crore (vs. ₹25.08 crore in FY25)
- FY26 Profit: ₹2.71 crore (vs. ₹2.73 crore in FY25)
- Dividend: ₹1.50 per share (15%)
- Subsidiary: Oleo Biosciences Private Limited (75% stake)
- Subsidiary Investment: Up to ₹2.25 crore
What to track next
Investors should closely monitor the commencement of commercial operations for Oleo Biosciences Private Limited and its revenue contribution. Updates on cost management and margin improvement strategies will also be important.